ArticleAMB Express2025
Catalytically active inclusion bodies of cold-adapted lipase: production and its industrial potential.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A CALB-like Cold-Active Lipolytic Enzyme fromMarine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Heterologous overexpression of certain recombinant proteins in E. coli often triggers the formation of inclusion bodies (IBs). Traditionally viewed as inactive aggregates, IBs are now known to sometimes retain native-like folding and catalytic activity, termed catalytically active inclusion bodies (CatIBs). In this work, we investigated the CatIBs formed by recombinant LipAMS8, a cold-adapted lipase from an Antarctic Pseudomonas sp., expressed in E. coli iBL21(DE3)/pET32b. Overexpression yielded abundant insoluble aggregates which were gently isolated using 50 mM Tris-HCl, 50 mM NaCl, 1% Triton X-100 (pH 8.0), and subsequently solubilized in Tris-HCl (pH 8.0) without denaturants. Scanning electron microscopy revealed rod-like protein particles ranging from ~ 100 nm up to 1 μm. Biochemical characterization demonstrated that these LipAMS8 aggregates indeed function as CatIBs, exhibiting enzymatic activity with a defined optimum temperature, broad pH stability, specific metal ion responses, and remarkable tolerance to organic solvents. The LipAMS8 CatIBs retained significant residual activity (≥ 50%) across a wide pH range and various temperatures and showed only modest activity loss after prolonged storage (over 13 weeks at 4 °C and 8 weeks at 25 °C, maintaining > 50% activity). Notably, these aggregates displayed higher stability in extreme conditions (pH and organic media) compared to typical soluble enzymes. This study is the first to characterize a naturally formed lipase CatIB, highlighting that LipAMS8 CatIBs are produced in vivo without any artificial tags. The LipAMS8 CatIBs combine high catalytic activity with exceptional stability and solvent tolerance, underscoring an alternative strategy to obtain cold-active lipases in immobilized form. Such robust CatIB biocatalysts are highly sought after in industries for diverse biotransformations in challenging conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.